Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
Authors
Sud, A
Thomsen, H
Law, PJ
Försti, A
da Silva Filho, MI
Holroyd, A
Broderick, P
Orlando, G
Lenive, O
Wright, L
Cooke, R
Peto, J
Canzian, F
Eeles, R
Kote-Jarai, S
Muir, K
Pashayan, N
the PRACTICAL consortium,
Hoffman, P
Nöthen, MM
Jöckel, K-H
von Strandmann, EP
Lightfoot, T
Kane, E
Roman, E
Lake, A
Montgomery, D
Jarrett, RF
Swerdlow, AJ
Engert, A
Orr, N
Hemminki, K
Houlston, RS
Publication Date
2017-12-01Journal Title
Nature Communications
ISSN
2041-1723
Publisher
Springer Nature
Volume
8
Number
1892 (2017)
Language
English
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Sud, A., Thomsen, H., Law, P., Försti, A., da Silva Filho, M., Holroyd, A., Broderick, P., et al. (2017). Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nature Communications, 8 (1892 (2017)) https://doi.org/10.1038/s41467-017-00320-1
Abstract
Several susceptibility loci for classical Hodgkin lymphoma (cHL) have been reported, however much of the heritable risk is unknown. Here, we perform a meta-analysis of two existing genome-wide association studies (GWAS), a new GWAS, and replication totalling 5,314 cases and 16,749 controls. We identify risk loci for all cHL at 6q22.33 (rs9482849, P=1.52 × 10-8) and for nodular sclerosis HL (NSHL) at 3q28 (rs4459895, P=9.43 × 10-17), 6q23.3 (rs6928977, P=4.62 × 10-55 11), 10p14 (rs3781093, P=9.49 × 10-13), 13q34 (rs112998813, P=4.58 × 10-8) and 16p13.13 (rs34972832, P=2.12 × 10-8). Additionally, independent loci within the HLA region are observed for NSHL (rs9269081, HLA-DPB1*03:01, Val86 in HLA-DRB1) and mixed cellularity HL (rs1633096, rs13196329, Val86 in HLA-DRB1). The new and established risk loci localise to areas of active
chromatin and show an over-representation of transcription factor binding for determinants of B-cell development and immune response.
Sponsorship
In the United Kingdom, Bloodwise (LLR; 10021) provided principal funding for the study. Support from Cancer Research UK (C1298/A8362 supported by the Bobby Moore Fund) and the Lymphoma Research Trust is also acknowledged. A.S. is supported by a clinical fellowship from Cancer Research UK. For the UK-GWAS, sample and data acquisition were supported by Breast Cancer Now, the European Union and the Lymphoma Research Trust. The UK-GWAS made use of control genotyping data generated by the WTCCC. For further information, please visit the publishr's website.
Funder references
Cancer Research UK (10124)
Cancer Research UK (16561)
National Cancer Institute (NCI) (U19CA148537)
MRC (G0401527)
MRC (G1000143)
MEDICAL RESEARCH COUNCIL (MR/N003284/1)
Cancer Research UK (CRUK-A16563)
Cancer Research UK (CRUK-A10118)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1038/s41467-017-00320-1
This record's URL: https://www.repository.cam.ac.uk/handle/1810/267360
Rights
Attribution 4.0 International, Attribution 4.0 International
Recommended or similar items
The following licence files are associated with this item:


